PHAT News and Press, Phathom Pharmaceuticals Inc. From 05/23/23

Anticipated FDA action date in Q4 2023; if approved, combined launch for Erosive GERD and H. pylori indications planned before year end If approved, vonoprazan would be the first innovative acid suppressant from a new drug class approved for the treatment of Erosive GERD in the U.S. i...

2023-05-11 10:00:13 ET Gainers: Organogenesis ( ORGO ) +23% . Arcturus Therapeutics ( ARCT ) +14% . Phathom Pharmaceuticals ( PHAT ) +14% . Pulse Biosciences ( PLSE ) +13% . PharmaCyte Biotech ( PMCB ) +11% . Losers: ImmunityBi...

2023-05-11 09:37:36 ET Phathom Pharmaceuticals ( NASDAQ: PHAT ) added ~8% on Thursday morning after Evercore ISI upgraded the biopharma, citing a potential FDA approval for its initial product candidate, vonoprazan, targeted at gastrointestinal disorders. “Phathoms&#x...

FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2023 and provided upda...

Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical characteristics Meta-analysis shows potassium-competitor acid blockers (PCABs), including vonoprazan, provide a long...

2023-04-25 08:00:00 ET Summary Phathom Pharmaceuticals, Inc. received a pair of CRLs that look fairly resolvable. If resolved, Phathom Pharmaceuticals will have vonoprazan launch in two indications, one very large, in Q4. They should have enough cash and loans to survive until...

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is one of today's top gainers. The company's shares are currently up 14.51% on the day to $10.02. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal di...

FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the fo...

2023-04-11 17:33:17 ET Gainers: PDF Solutions ( PDFS ) +4% . Phathom Pharmaceuticals ( PHAT ) +3% . Frontier Communications Parent ( FYBR ) +3% . InflaRx ( IFRX ) +2% . PENN Entertainment ( PENN ) +2% . Losers: Melco Reso...

2023-04-04 09:38:49 ET Phathom Pharmaceuticals ( NASDAQ: PHAT ) stock rose ~10% on Tuesday after the company said it expects to refile an application seeking approval of vonoprazan to treat erosive esophagitis in Q2 2023 following a meeting with the U.S. FDA. In Februa...